Clinical deterioration after sildenafil cessation in patients with pulmonary hypertension
Authors:
Open Access
- 1 October 2008
- journal article
- research article
- Published by Taylor & Francis in Vascular Health and Risk Management
- Vol. ume 4 (5) , 1111-1113
Abstract
Clinical deterioration after sildenafil cessation in patients with pulmonary hypertension Anne M Keogh, Andrew Jabbour, Christopher S Hayward, Peter S MacdonaldHeart Lung Transplant Unit, St Vincent’s Hospital, Sydney, New South Wales, Australia Sildenafil is a selective inhibitor of phosphodiesterase type 5 (PDE-5). Its chronic administration has been shown to improve exercise capacity, World Health Organization functional class, and haemodynamics in patients with symptomatic pulmonary arterial hypertension (PAH). There is however, no data describing the clinical consequences of sudden cessation of sildenafil treatment. In this series, 9 patients with NYHA Class II–IV PAH who were stable on 2 months of sildenafil monotherapy, had their sildenafil ceased to accommodate a 2-week washout period, required for enrollment in research involving an endothelin receptor antagonist. Six minute walk distance (SMWD) and clinical assessments were performed before cessation of sildenafil, and again 2 weeks later. Over the course of this 2-week washout period, 6 of the 9 patients reported increased breathlessness and fatigue, 1 of these was hospitalized with worsening right heart failure. The SMWD fell in 6 patients, with falls of greater than 100 m recorded in 4 patients. This was accompanied by a worsening of NYHA Class from 2.5 ± 0.2 to 3.1 ± 0.1 (mean ± SEM, p = 0.01). These data indicate that sudden cessation of sildenafil monotherapy, in patients with PAH, carries with it a significant and unpredictable risk of rapid clinical deterioration. We recommend that if sildenafil needs to be ceased, it would be more prudent to consider concurrent vasodilator therapy before the gradual cessation of sildenafil.Keywords: sildenafil, pulmonary hypertension, phosphodiesterase inhibitorKeywords
This publication has 15 references indexed in Scilit:
- Chronic Sildenafil Lowers Transpulmonary Gradient and Improves Cardiac Output Allowing Successful Heart TransplantationEuropean Journal of Heart Failure, 2007
- Sildenafil Citrate Therapy for Pulmonary Arterial HypertensionNew England Journal of Medicine, 2005
- Early haemodynamic benefit of sildenafil in patients with coexisting chronic thromboembolic pulmonary hypertension and left ventricular dysfunctionVascular Pharmacology, 2005
- Sildenafil for pulmonary hypertension after heart transplantationThe Journal of Heart and Lung Transplantation, 2004
- Interventional and surgical modalities of treatment for pulmonary arterial hypertensionJACC, 2004
- Effect of sildenafil on the acute pulmonary vasodilator response to inhaled nitric oxide in adults with primary pulmonary hypertensionThe American Journal of Cardiology, 2002
- Oral Sildenafil Is an Effective and Specific Pulmonary Vasodilator in Patients With Pulmonary Arterial HypertensionCirculation, 2002
- Combination Therapy with Oral Sildenafil and Inhaled Iloprost for Severe Pulmonary HypertensionAnnals of Internal Medicine, 2002
- Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled studyThe Lancet, 2001
- Effect of Inhaled Iloprost Plus Oral Sildenafil in Patients With Primary Pulmonary HypertensionCirculation, 2001